Update on Scheduled FDA Advisory Committee Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mesoblast (MESO) Receives Backing from FDA Panel for Remestemcel-L
August 13, 2020 5:05 PM EDTMesoblast (NASDAQ: MESO) Receives Backing from FDA Panel for Remestemcel-L
FDA ADCOMM VOTE: Do the available data support the efficacy of remestemcel-L in pediatric patients with steroid-refractory aGVHD?
8-Yes
2-No
0-Abstain
aGVHD = acute graft-versus-host disease$MESO #Ryoncil #MesenchymalStromalCells #StemCellTherapy
... More
Despite Concerns, Cantor Fitzgerald Thinks Mesoblast's (MESO) Ryoncil Could Be Approved
August 11, 2020 8:19 AM EDTCantor Fitzgerald analyst Louis Chen weighed in on Mesoblast Limited (NASDAQ: MESO) after shares were slammed 25%+ following FDA briefing documents that raised the "Fear Factor" about Ryoncil, in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children. Chen thinks Ryoncil could be approved despite the fears.
The FDA AdCom for MESO's Ryoncil is on 8/13 from 8am to 5pm ET. The FDA's Oncologic Drugs... More
